Downstream of Ozempic -- The 2nd, 3rd, and 4th Order Effects

Two years in, the GLP-1 trade is no longer "who makes the drug." Novo Nordisk and Eli Lilly are priced. The trade now is every category that gets reshaped by the body composition shift happening at scale across 15M+ Americans -- and the number keeps moving up.

Victoria's Secret's Q1 2026 print was the clearest public-market proof yet that the second-order effects are real and now legible in earnings: +15% net sales to $1.6B, net income up 20x year over year, guiding toward $7B+ annually. Bernstein puts the total apparel spend impact from GLP-1 adoption at ~$13B per year. Circana flagged bras as the leading indicator -- when women drop two cup sizes, the entire intimates wardrobe gets replaced. That's a second-order effect nobody underwrote in 2023.

Here's the map below the waterline.

The First-Order Recap (Fast)

• ~15M+ Americans currently on Wegovy, Ozempic, Mounjaro, or Zepbound
• Compounded GLP-1s expanded the TAM 3-5x on price before Lilly and Novo started fighting back through FDA
• RFK Jr. moved 14 previously FDA-banned peptides back to legal status in early 2026; peptide search volume is up 6x
• Women are the primary adopters -- Morning Consult and RAND data both show Gen X women ages 50-64 as the heaviest user cohort, with millennial women as the fastest-growing segment
• The average user loses 15-22% of body weight over 12-18 months. That's not a diet. That's a new body.

Everything below is what that new body buys.

Second Order: The Categories Already Moving

Intimates and apparel refresh

VS is the headline. But the full picture is wider. Skims (Kim Kardashian's shapewear-to-full-intimates brand, valued at $4B) is structurally positioned for a body-in-flux consumer -- it designs for every size and sells the idea of your body right now, not a target body. Knix (acquired by Essity for $400M) and ThirdLove are both building for the same shift.

Denim is next. Levi's already noted on its earnings call that customers are buying new fits -- not because trend changed, but because their bodies did. The replacement cycle in denim is compressing from 2-3 years to under 12 months for GLP-1 users.

Swim will be the next VS-style print. Watch Andie Swim and Summersalt -- both direct, both data-native on fit, both serving the 35-55 woman who is the exact demographic on GLP-1s.

Facial aesthetics: the "Ozempic face" correction market

Rapid weight loss depletes facial fat. The procedure market that corrects for that is now a named category. Filler, fat transfer, thread lifts, and Sculptra (poly-L-lactic acid, which stimulates collagen) are all up. Galderma (Sculptra, Restylane) and Allergan Aesthetics (Juvederm, Botox) are direct beneficiaries. The med-spa model -- Ideal Image, Ever/Body, Milk + Honey -- is growing into a repeat-visit business as GLP-1 users maintain the correction.

Body composition: strength, protein, and lean mass preservation

The clinical guidance on GLP-1s now almost universally includes resistance training and protein targets to prevent muscle loss alongside fat. This has produced real consumer behavior. Momentous (evidence-based supplements, partnered with 150+ pro sports teams), Maui Nui Venison (wild-harvested meat at elite protein density), and Thorne (now public, science-first supplement brand) are all growing in a tailwind they didn't manufacture.

Tonal, Tempo, and the home-strength-training category had a COVID spike and a hangover. The GLP-1 cohort is the re-ignition event. Maintaining muscle on a GLP-1 regimen requires consistent resistance work -- and that consumer is high-income and highly compliant.

Alcohol: the quiet casualty

GLP-1s reduce cravings broadly, not just for food. Alcohol consumption among GLP-1 users is down 30-40% in multiple studies. Beer and wine volumes were already declining structurally with Gen Z's low-alcohol behavior. GLP-1 adoption in the 35-55 cohort is now hitting categories that thought they were safe from the trend.

Athletic Brewing (non-alcoholic, raised $50M+, now the largest NA beer brand in the US), Ghia, and Proxies are beneficiaries. The premium spirits category is more insulated (smaller volumes, higher per-occasion spend), but mainstream beer has a structural problem that GLP-1 adoption is accelerating.

Snack and CPG: the reformulation imperative

Portion appetite is down. High-sugar high-fat products are the first to lose. Nielsen data shows salty snack volume declining in GLP-1-dense zip codes. The companies that will survive are reformulating around protein, fiber, and satiety -- not hedonic taste engineering.

Chomps (meat sticks, $100M revenue, protein-first positioning), RXBar, and Kind are structurally better positioned than legacy snack. The company to watch on the short side of this is any large-cap CPG with a portfolio that is majority indulgence-category and has not started reformulating.

Third Order: Where the Alpha Still Is

The peptide platform layer

RFK Jr.'s move to legalize 14 previously FDA-banned peptides -- including BPC-157, TB-500, and PT-141 -- reopened a market that had been driven underground by the FDA's compounding crackdowns. The legitimate peptide platform hasn't been built yet. What exists: Limitless Life Nootropics, underground research chemical suppliers, and the grey-market gray zone. The company that builds a clean, medically supervised, legally compliant peptide prescription platform is building the next Hims.

Hims & Hers (HIMS on NYSE) is already moving into GLP-1 territory. Its compounded semaglutide play generated over $100M in quarterly revenue before running into Lilly and Novo's lobbying wall. Watch how it repositions into adjacent peptides and longevity compounds as compounding access tightens.

Ro, Eden Health, and Mochi Health are all building the telehealth routing layer for body composition interventions -- not single-drug DTCs but multi-modal platforms.

The compliance and enforcement arbitrage

Compounded GLP-1s are being pulled back. Lilly won an FDA ruling in early 2026 restricting compounded semaglutide. The consumer demand doesn't disappear -- it gets displaced. There is a $5B+ orphaned market looking for a compliant alternative. The first platform that routes that demand cleanly into: (a) brand-name GLP-1 access at lower cost, (b) peptides under the new legal framework, or (c) non-GLP-1 body composition protocols -- wins a massive arbitrage window that closes in 12-18 months.

The "aesthetic identity" bundle

Nobody has bundled apparel refresh + aesthetics procedures + body composition support into a single consumer experience. The consumer is doing it herself by visiting VS, then a med-spa, then a PT, then an online supplement store. The brand that owns the GLP-1 transformation journey as a category -- think what Peloton was trying to be, but for body composition in your 40s -- hasn't been built.

Found and Calibrate are trying to be that platform. Neither has cracked the retention and bundling problem yet.

Fourth Order: The Legacy Shorts

The under-discussed part of this trade. Categories that don't adapt will lose volume permanently:

• Mainstream beer and wine: volume down structurally, GLP-1 accelerating it
• High-indulgence snack CPG: Doritos, Lay's, mainstream candy -- the exact SKUs GLP-1 users report dropping first
• Fast casual at mid-tier portion sizes: portion economics are breaking. The category that was safe from fast food disruption because it offered "quality" is now getting hit on the quantity side
• Legacy apparel mid-market: anyone selling the same size runs they sold in 2022 without investing in a smaller-size or resizing infrastructure

The short basket isn't dramatic. It's a slow bleed across categories that assumed the American appetite was stable.

The Investable Framework

Four layers, descending from infrastructure to brand:

1. Molecule layer -- peptide platforms, novel GLP-1 delivery (oral, patches), compounding infrastructure under new regulatory clarity. Highest risk, highest upside.
2. Body composition layer -- protein, strength, recovery, lean mass preservation. Tailwind is structural and multi-year. Lower risk, clear comps.
3. Aesthetic and identity layer -- intimates, derm, apparel refresh, the Sculptra/Galderma aesthetics trade. VS already printed. Next will be swim, denim, and med-spa chains.
4. Picks-and-shovels routing -- Hims, Ro, Mochi, Eden as the telehealth layer that routes all of the above. Platform dynamics favor whoever gets to multi-modal first.

The connecting thread to the millennial midlife crisis piece: the GLP-1 adopter and the millennial in the well-being trough are the same person making the same decision. They are buying who they want to be next, not what they're supposed to own. That's the unified consumer thesis for 2026.